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ABSTRACT 
Objective: A unicentre, prospective study was carried out to investigate the behavioral effects of lacosamide as adjunctive therapy with refractory 
partial epileptic children in tertiary care hospital with prior approval from the Institutional Human Ethical Committee. 
Methods: Seventy nine patients (age 5- 15 years) with refractory partial epilepsy patients were enrolled after fulfilling the inclusion and exclusion 
criteria. And those who had failed ≥  2 antiepileptic drugs in whom lacosamide was added as add on drug therapy. Lacosamide tablets was 
administered orally twice daily. Influence of Lacosamide on children’s behaviour was performed at every visit of titration, maintenance period and 2 
follow ups at monthly interval. Patient’s caregiver or investigator observed adverse events were recorded.  
Results: Out of 79 patient’s, 53 were males and 26 females. Patients completing 3 months, of study therapy showed significant (p<0.001) decrease 
in frequency of seizure and improvement in behaviour at end of the treatment period and few patients had mild transient adverse events. Three 
patients were dropped from the study.  
Conclusion: Lacosamide signifies a beneficial drug that is effective and concurrently improved patient’s behaviour in refractory partial epilepsy 
paediatric patients. 
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INTRODUCTION 
Epilepsy is a neurological disorder characterized by recurring 
seizures and is generally defined by two or more unprovoked 
seizures with abnormal and excessive discharge from set of neurons 
in the brain. The condition comprises different seizure types and 
syndromes [1-2]. This has created complexities in establishing the 
incidence and prevalence and prognosis of epilepsy [3]. It was 
estimated that the risk of premature death among individuals with 
epilepsy is 2–3 times higher than in the general population [4]. 
There may be about 5-10 million people with epilepsy (PWE) in 
India accounting for almost one-fifth of the global figures [5]. Many 
people die each year from causes directly related to epilepsy. 
Around half of these are due to sudden unexpected death in epilepsy 
(SUDEP). However, establishing the exact number and nature of 
epilepsy-related deaths from national data is difficult [6]. 
Prevalence increased over the age-span in both sexes, although was 
higher in men over 55 years old than in women of the same age 
group. Prevalence was <2 per 1000 in the under 5-years-old age 
group increasing to over 4 per 1000 in 5–15 years old and also 
increased to 15.1 per 1000 in men and to 11.0 per 1000 in women 
aged ≥ 85 years. This confirms earlier findings that incidence and 
prevalence is highest in the elderly population [7, 8]. 
Epilepsy does not have one underlying cause. Attributable cause in 
adults include hippocampal sclerosis, cortical dysgenesis, vascular 
insults, head injuries and drug or alcohol abuse [9]. Onset of epilepsy 
can occur at any age, but is most common during childhood or older 
age. Not all patients with seizures develop the chronic condition; 
some children have seizures that do not progress into adulthood and 
some adults may experience remission.  
The most commonly used AED (antiepileptic drugs) are 
carbamazepine, valporic acid and phenytoin [9, 10]. The newer 
drugs are licensed for adjunctive therapy only lacosamide (LCM), 
lamotrigine (LTG) and oxcarbamazepine (OXC) are licensed for 
monotherapy or adjunctive therapy [11]. Despite the introduction of 
several new antiepileptic drugs (AEDs) over the past 20 years, about 
30% of patients with epilepsy become refractory to current 
treatments or experience significant adverse events [12-14]. 
Therefore, attempts are being made to identify novel drugs 
therapies that reduces the seizure frequency and may improve 
Lacosamidelife.ofqualitypatient’s pharmacokinetic-
pharmacodynamics (efficacy) analysis was performed based on the 
pooled data from the 3 efficacy trials for partial-onset seizures. 
Lacosamide exposure is correlated with the reduction in seizure 
frequency [15]. Lacosamide showed favourable pharmacokinetics 
properties, a low potential for drug - drug interactions and is thus 
well suited for polytherapy and use in children [16]. Although it is 
not approved for use in children, but have an active role in the 
management of pediatric epilepsy because of focal seizures are the 
most common seizure in children [17]. The goal of the present 
prospective study was to assess the influence of lacosamide on 
behaviour of children with refractory partial epilepsy using 
Connor’s rating scale index [18]. It was part of our study on effect 
and tolerability of lacosamide in children with refractory partial 
epilepsy [19].  
MATERIALS AND METHODS 
Patients  
This is an open label study, out of 531 screened patients, 79 patients 
were enrolled and 3 (3.79%) patients were dropped from the study. 
76(96.20%) patients completed the titration, maintenance period 
with two follow up period of one month each.  
Study design 
This is a prospective study carried out for a period of 30 months. 
Prior approval from the Institutional Human Ethics Committee was 
obtained. In this study all patients or their legal representatives gave 
written informed consent before trial participation. Patients were 
enrolled based on inclusion criteria of those aged between 5-15 
years with uncontrolled focal epilepsy, who have had at least 3 
months duration of epileptic seizures and not controlled after 
sequential or additives use of at-least two Antiepileptic drugs 
(AEDs). Diagnosis of seizures and epileptic syndromes was based on 
the classification of Epileptic seizures (Commission on Classification 
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and Terminology of the International League against Epilepsy 2011 
[20] after going through their electroencephalography (EEG) reports 
and or either magnetic resonance imaging (MRI). 
Lacosamide was administered orally in the form of tablets with 
increment dose of 25mg twice a week followed by 50mg twice a day 
for the remaining period. During the study period, in case of any 
adverse event or any discrepancies, patient were said to report or 
call principal investigator (PI). 
Study assessments 
Routine examinations of vital signs, body weight, physical and 
neurologic examinations were done at every visit. Plasma samples 
were drawn to investigate transaminase (SGOT/SGPT) levels, 
electroencephalogram (EEG) and electrocardiogram (ECG) were 
recorded.  
Patients were categorized based on etiological classification 
idiopathic/genetic, structural/metabolic and cryptogenic/ unknown. 
Seizure type was based on the semiology, EEG findings (temporal 
epilepsy, focal lobe epilepsy, occipital lobe epilepsy, centro-temporal 
epilepsy, multifocal and others). 
In our study, we also measured tolerability based on global 5 point 
scale (score of 5 was given when there was decrease in side effects; a 
score of 4 when there were no side effects; score of 3 when there 
was one new side effect; score of 2 when there were 2-3 side and 
score of 1 when there were > 3 side effects). Patients who were 
unable to tolerate protocol medication and those experiencing 
adverse effects were made to discontinue treatment.  
Attenders/caretakers were provided with record diary card, which 
captures the details of per month treatment days, seizure 
occurrence, loss of consciousness, total number of seizure for 24 
hours, duration of seizure and medication taken in the morning and 
evening, from the beginning of titration period till last evaluation. 
Statistical analysis 
Outcome of lacosamide in refractory partial epilepsy was measured 
using SPSS 20.0 for Windows (IBM Corporation, Armonk, NY, USA) was 
used for the statistical analysis. Statistical significance was set at p < 0.05. 
RESULTS 
Patient disposition 
Out of 531 screened patients, 79 patients were enrolled with intention 
to treat (ITT). 76(96.2%) patients completed 3 months of maintenance 
period. Three (3.79%) patientsdropped from the study. One (1.26%) 
patients developed severe hyperactivity and behavioural changes and 
other two (2.53%) withdrew from the study because of vomiting and 
lack of seizure control as shown in Table 1. 
Demographics data and patient characteristics 
The clinical characteristics of 79 patients with refractory partial 
epilepsy are presented in Table 2. Patient mean age was 
8.84±3.09years with age range of 5 - 15years; of which 53 (67%) 
maleand 26 (32.9%) females with mean weight of 24.44±9.84. The 
mean age at epilepsy onset in males 6.46±3.49 and females 
6.38±3.39. Forty nine (62.02%) patients continued investigational 
drug even after end of the study (EOS) treatment period was and 30 
(37.9%) stopped afterend of the study (EOS). 
 
Table 1: Patient disposition 
S. No. Study details Value 
1 No. of patient enrolled 79 
2 No. of patients completed during study period 76 (96.2%) 
3 Patients completed 3 months of treatment duration  46 (58.2%) 
4 No. of patients continued even after treatment period 30 (37.9%) 
5 No. of patients discontinued the study 3 (3.79%) 
 
Table 2: Demographic data and patient characteristics 
S. No. Characteristics Value 
1. Age, year 8.84±3.09 
2. Sex, n (mean±SD) 
Male (53) 8.93±3.09 
Female (26)  8.65±3.31 
3. Weight, Kg (mean±SD) 24.44±9.84 
4. Follow up Duration on Lacosamide 
Continued  49 (62.02%) 
Discontinued 30 (37.97%) 
5. Onset of Seizure(mean±SD) 
Males 6.46±3.57 
Females 6.38± 3.39 
 
Table 3: Drugs -Antiepileptic therapy process 
S. No. Antiepileptic Drugs n (%) 
1.  LCM + SVA 19 (24%) 
2.  LCM + SVA + 1AED 17 (21.5%) 
3.  LCM + SVA + 2AED 3 (3.8%) 
4.  LCM + LMT 1 (1.3%) 
5.  LCM + LMT + 1AED 2 (2.53%) 
6.  LCM + LEV + 1AED 7 (8.9%) 
7.  LCM + LEV + 2AED 2 (2.5%) 
8.  LCM + CBZ 6 (7.6%) 
9.  LCM + CBZ + 1AED 5 (6.3%) 
10.  LCM + CBZ + 2AED 1 (1.3%) 
11.  LCM + 1AED 12 (15.1%) 
12.  LCM + 2AED 4 (5.06%) 
Co-administered Drugs:  SVA: sodium volporic Acid, CBZ: Carbmazepine, LMT: Lamotrigine LEV: Levetiracetam, Other Antiepileptic drugs (AEDs)includes: 
CLB: Clobazam,  OXC: Oxcarbamazepine, TPM: Topiramate, PHT: Phenytoin, ZNS: Zonisamide, PB:  Phenobarbitone, CNZ:  Clonazepam, NPM:  Nitrazepam. 
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During the study period, concomitant administration of one or more 
antiepileptic drug (AED) along with lacosamide (LCM) was 
evaluated. Lacosamide with sodium valporic acid (SVA) was 24%, 
followed by addition of another AED drug was 21.5% and two AED 
was 3.8% respectively, was used in highest consumed drug in this 
study period, when compared to other co-administered AED. 
Lacosamide with one AED was 15.1% showed second highest 
consumed drug during the study period. Remaining AED drugs along 
with LCM are shown in Table 3. 
Co-administered AED drugs Includes 
SVA: Sodium valporate, CLB: Clobazam, CBZ: Carbmazepine, OXC: 
Oxcarbamazepine, LMT: Lamotrigine LEV: Levetiracetam, TPM: 
Topiramate, PHT: Phenytoin, ZNS: Zonisamide, PB: Phenobarbitone, 
CNZ: Clonazepam, NPM: Nitrazepam. LCM: Lacosamide 
Diseases and Drug characteristics with behavior of children 
As shown in Table 4, among the study population, majority of the 
patients 30 (38.1%) had occipital lobe of epilepsy, followed by 
frontal lobe epilepsy in 20 (25.3%) patients. Based on etiological 
classification 19(24.1%) with idiopathic/genetic, 50(63.3%) with 
structural/metabolic and 10(12.7%) patients with cryptogenic/ 
unknown. 
The behavioural life of the remaining 76 patients was assessed using 
25 item questionnaire that was filled by parents/ care takers/ 
attenders. Mean total scores at baseline was 48.04 ± 10.57; after 3 
month of maintenance period, mean behavioral life was 19.27 ± 
08.03 and subsequent follow up visit was. The scores improved 
significantly with treatment (ANOVA test with P < 0.001). The 
behavioural scores remained relatively constant from baseline to 
treatment period to all subsequent follow up visits was 19.05 ± 05.29. 
  
Table 4: Diseases and Drug characteristics 
S. No. Clinical Findings Values 
Males Females 
1 Seizure Type   
Temporal Lobe Epilepsy 3 (5.8%) 1 (3.84%)  
Frontal Lobe Epilepsy 13 (25.0%) 7 (26.6%) 
Occipital Lobe Epilepsy 24 (44.2%) 6 (23.0%) 
Centro temporal Epilepsy 01 (1.9%) 3 (11.5%) 
Multifocal 06 (11.5%) 9 (34.5%) 
Others 06 (11.5%) 0 (0.0%) 
2 Tolerability 
0 03 (3.8%) 
1 04 (5.1%) 
2 11 (13.9%) 
3 32 (40.5%) 
4 27 (34.2%) 
5 02 (2.5%) 
3 Seizure frequency per 28 days:  
Mean ± SD - Baseline  13.3 ± 24.11 
End of the study seizure frequency:   
Mean ± SD  4.53 ± 13.22 
% Reduction (p<0.001)# 59.9 ± 99.9 : 
4 Connors Comprehensive Behaviour Rating Scale  
Baseline - Mean ± SD  48.04 ± 10.57 
End of the study - Mean ± SD* 19.27 ± 08.03  
Follow Up*  19.05 ± 05.29 
#p<0.001, showed significant difference using Wilcoxson signed ranks test., *P < 0.001, showed significant difference using ANOVA test 
 
Efficacy and tolerability 
At the end of the study (EOS), 76 patients entered the maintenance 
period with a mean reduction in seizure frequency per 28 days from 
13.35 ± 24.12 at baseline to 4.53 ± 13.23 at the EOS (Wilcoxson 
signed ranked test p < 0.001). At the end of the follow up period, 
mean reduction in seizure was 3.9 ± 11.81 as shown in Table 4. 
Tolerability was assessed by investigator and patients at the last 
visit on a 5 point scale. Two (2.5%) patients had reduction in side 
effects after lacosamide therapy; 27 (34.2%) did not have any new 
side effects. Thirty two patients (40.5%) had one new side effect 
while 11 patients (13.9%) had 2-3 side effects. Four of our patients 
(5.1%), developed more than 3 side effects as shown in Table 4. 
Adverse effects 
The common adverse events were hyperactivity, ataxia, drowsiness, 
insomnia, weight gain, nausea, abdominal discomfort, giddiness, 
headache, and vomiting. Most of the reported side effects were mild 
to moderate in intensity and did not need discontinuation of 
treatment. Overall results of clinical laboratory tests, physical 
examinations, neurological examinations and assessments of vital 
signs did not reveal any changes with lacosamide treatment. 
Lacosamide was withdrawn in three patients (3.79%). Reasons for 
discontinuation were unsatisfactory seizure control (one patient) 
and aggressive behavior (one patient) during the titration and one 
patient had severe vomiting.  
DISCUSSION 
This prospective demonstrates that adjunctive therapy with twice-
daily dose of up to 50mg of oral lacosamide not only reduces seizure 
frequency with better safety profiles and fewer side effects in 
pediatric patients with uncontrolled epilepsy. The study confirms 
the clinical efficacy and tolerability of lacosamide in refractory 
epilepsy and corroborates findings from previous studies. 
In randomized controlled trials conducted in adults, lacosamide has 
shown to be an effective and safe AED in treating refractory seizures, 
with 30-40% of patients achieving a ≥ 50% reduction in seizure 
frequency at doses of 400-600 mg/day [20-23]. 
In a multicenter, prospective study by Verrotti et al. (2013) compared 
lacosamide in pediatrics and adults. A total of 118 patients (59 group 
A, 59 group B) with uncontrolled generalized and focal epilepsy were 
enrolled. At 3-month evaluation, 118 treated patients 56 subjects 
(47.4% group A; 47.4% group B; p = 0.8537) experienced at least 50% 
reduction in seizure frequency respectively [15]. 
Diagnosis criteria used in our epilepsy study is similar to previous 
studies evaluating lacosamide therapy in children [20-22,24] . 
butwith large sample size. 
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In our study, we compared baseline seizure frequency with 2 month 
of maintenance period, end of the study (EOS) and after 2 follow ups. 
It was found that at 2 months of the treatment period the mean % 
reduction in seizure was 50.2(p<0.001) and at the end of the study 
there was increase in mean reduction of seizure from baseline to 
59.9% (p<0.001). At the end of two months follow ups period the 
mean reduction found to be 67.5% (p<0.001).  
Lacosamide has been reported to be a well-tolerated, relatively safe 
drug [25].  Adverse reactions, such as dizziness, headache, diplopia, 
nausea and somnolence, drowsiness, dizziness observed in pediatric 
case reports and case series [25-28]. Adverse events were noted in 
half of our subjects. The most common adverse event observed in 
our study were almost congruent with those reported by Gavatha et 
al (2011). Adverse effects seen with lacosamide in adults are dose-
related [25] and reversible upon discontinuation or dose reduction.  
Lacosamide was discontinued in only one patient (1.26%) because of 
severe hyperactivity, aggression and inattention one week after starting 
the drug. It continued for one month till the drug was continued and the 
behavioral symptoms reverted back to normal status after the drug was 
stopped [29] and remaining two (2.53%) were withdrawn from study 
due to vomiting and lack of seizure control. 
CONCLUSION  
In conclusion, lacosamide is one of the newest additional drug to the 
AED category and represent a possible option, currently indicated 
for refractory partial epilepsy. Lacosamide showed favorable safety, 
tolerability profile with no increase in seizure frequency and 
improved children behavior during the study period. 
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